3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1
1
Status
Completed
3
Terminated
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Genitourinary
2
Thoracic
1
Conditions
Urinary Bladder Neoplasms
2
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cyclophosphamide
1492
Cisplatin
1414
Paclitaxel
1317
Radiotherapy
1261
Carboplatin
1250
Gemcitabine
1215
Docetaxel
1109
Bevacizumab
1030
Fluorouracil
894
Doxorubicin
792
Dexamethasone
748
Rituximab
719
Capecitabine
716
Oxaliplatin
700
pembrolizumab
680
Etoposide
678
Irinotecan
634
Filgrastim
621
Cytarabine
586
Leucovorin
579
Nivolumab
558
Vincristine
515
Prednisone
475
Cetuximab
465
Bortezomib
459
Erlotinib Hydrochloride
456
Trastuzumab
447
Methotrexate
438
Lenalidomide
427
Pemetrexed
420
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Completed
×
Interventional
×
Mycobacterium w vaccine
×
Clear all
NCT00694915
2021-08-17
STCC
Cadila Pharnmaceuticals
Phase 2
Completed
122 enrolled
NCT00680940
2012-08-07
NSCLC
Cadila Pharnmaceuticals
Phase 2
Completed
221 enrolled
NCT00694798
2012-05-03
STCC
Cadila Pharnmaceuticals
Phase 1
Completed
22 enrolled